Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction

Yasuhiko Sakata, Hiroshi Sato, Kunihiro Kinjo, Kenshi Fujii, Kazuhisa Kodama, Jun Tanouchi, Masayoshi Mishima, Hideo Kusuoka, Daisaku Nakatani, Hiroya Mizuno, Masahiko Shimizu, Masatsugu Hori

Research output: Contribution to journalArticle

Abstract

We conduct a prospective randomized study, the OACIS-LIPID, to determine whether early use of pravastatin can prevent secondary cardiac events in patients with acute myocardial infarction (AMI) and hyperlipidemia (HL). Three hundred and fifty Japanese patients with AMI and mild to moderate HL are randomly assigned to receive or not to receive pravastatin in an open-labeled fashion. The primary dose of pravastatin is 10 mg per day, which is a standard dose for the Japanese population. Both groups receive dietary counseling. Over a 9-month follow-up period, the combination of the endpoints (death, nonfetal myocardial infarction, unstable angina, noncardiac rehospitalization, revascularization and nonfetal stroke) will be evaluated. The results of the OACIS-LIPID study will determine the utility of a practical dose of hydroxymethylglutaryl coenzyme A reductase as an early intervention in AMI.

Original languageEnglish (US)
Pages (from-to)193-196
Number of pages4
JournalHeartDrug
Volume5
Issue number4
DOIs
StatePublished - Oct 1 2005

    Fingerprint

Keywords

  • Acute myocardial infarction
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Sakata, Y., Sato, H., Kinjo, K., Fujii, K., Kodama, K., Tanouchi, J., Mishima, M., Kusuoka, H., Nakatani, D., Mizuno, H., Shimizu, M., & Hori, M. (2005). Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction. HeartDrug, 5(4), 193-196. https://doi.org/10.1159/000089599